Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective CoV-2 mRNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"LSP","pharmaFlowCategory":"D","amount":"$38.1 million","upfrontCash":"Undisclosed","newsHeadline":"eTheRNA Nabs \u20ac34M For mRNA Vaccine Including COVID-19 Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"BELGIUM","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"ConserV Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"European Commission","pharmaFlowCategory":"D","amount":"$8.3 million","upfrontCash":"Undisclosed","newsHeadline":"Consortium Led by etheRna Immunotherapies Awarded Eu Commission Tiger Grant of Eur 6.9 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"eTheRNA immunotherapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"eTheRNA Immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"VUB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"eTheRNA and VUB Expand Strategic Collaboration to Engineer Next Generation mRNA Therapeutics with TetraMix\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by eTheRNA immunotherapies

    Menu

    eTheRNA immunotherapies

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              eTheRNA immunotherapies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              eTheRNA Immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement

              Details:

              eTheRNA will receive exclusive worldwide rights to commercialise a new library of novel ionizable lipids, co-developed with the research group of Prof. Bruno De Geest from Ghent University, for a new generation of lipid nanoparticle (LNP) formulations.

              Lead Product(s): mRNA-based Immunotherapies

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Recipient: Ghent University

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration July 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              eTheRNA immunotherapies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              eTheRNA and VUB Expand Strategic Collaboration to Engineer Next Generation mRNA Therapeutics with TetraMix®

              Details:

              Clinical and preclinical data have demonstrated clinical safety of TriMix, together with its ability to amplify immune responses in multiple disease indications. Extension to proven TriMix® adjuvant technology intended to boost dendritic cell activation.

              Lead Product(s): TetraMix-based Vaccine

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: VUB

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              eTheRNA immunotherapies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Consortium Led by etheRna Immunotherapies Awarded Eu Commission Tiger Grant of Eur 6.9 Million

              Details:

              The grant will be used to accelerate the development of a novel, potentially best-in-class therapeutic mRNA cancer vaccine for treating recurrent/metastatic HPV16+ cancers such as head and neck cancer, cervical cancer, anogenital cancer.

              Lead Product(s): mRNA cancer vaccine

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: European Commission

              Deal Size: $8.3 million Upfront Cash: Undisclosed

              Deal Type: Funding March 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              eTheRNA immunotherapies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases

              Details:

              The partnership will initially focus on the development and evaluation of mRNA vaccine formulations against human immunodeficiency virus (HIV), with the objective of identifying a lead formulation to move forward to clinical development.

              Lead Product(s): mRNA vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Vaccine

              Recipient: ConserV Bioscience

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership March 04, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              eTheRNA immunotherapies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              eTheRNA Nabs €34M For mRNA Vaccine Including COVID-19 Candidate

              Details:

              Proceeds of the financing will fund continued development and commercialization of proprietary mRNA technologies and a range of therapeutic products.

              Lead Product(s): SARS-CoV-2 mRNA vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: LSP

              Deal Size: $38.1 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing June 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              eTheRNA immunotherapies

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective CoV-2 mRNA Vaccine

              Details:

              The new vaccine is intended specifically for populations at high risk. It is also planned to guard against potential viral mutations by targeting conserved epitopes of the entire CoV-2 genome.

              Lead Product(s): mRNA vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY